Search results for: 'past growth chambers'

20 Dec 2022  |  Global  |  Technology Research

Advances and Growth Opportunities in RNA Vaccines

Technology Innovations and Investments Bolster Next-generation Prophylactic and Therapeutic RNA Vaccines

Infographics

×

RNA therapeutics and vaccines have been around for a long time, but the COVID-19 pandemic enabled their mass-market commercialization. Industry players saw mRNA vaccines developed for COVID-19 as effective for reducing the impact of the SARS-CoV-2 virus in populations. Moderna emerged as the first player to develop and commercialize an mRNA vaccine...

Skin microbiome industry has been rapidly evolving since the past few years and is likely to witness new innovations in the near future. Apart from emerging new start-ups in this area, several leading cosmetic and industry participants are likely to shift focus towards emerging microbiome-based beauty platforms.As the consumer focuses towards the...

05 Jun 2018  |  Global  |  Market Research

Anti-Aging Therapies and Services Market—Trends and Growth Opportunities, Forecast to 2022

Focus on Integrative Solutions Combining Dietary Supplements and Aesthetic Solutions with Clinical Therapeutics as the Market Moves Toward a ‘Prevent-Manage-Repair’ Continuum

Infographics

×

Key Issues Addressed

The rapidly aging global population is placing immense pressure on healthcare systems across countries and regions. The improvement in life expectancy levels has created a large cohort of aged patients who suffer from one or more chronic diseases. Traditionally, the approach towards the management of this issue has been on ‘repair’, i.e., treatment...

The impressive advances in life sciences research and development (R&D) befallen in the past two-three years are playing a leading role in the transformation of the healthcare industry. A myriad of new developments in the fields of gene and cell therapies, empowered with nanotechnology advances, omics technologies and novel smart molecules approach...

In 2003, the first human genome sequence was produced, with a production cost between $500 million and $1 billion. However, since 2008, when next-generation sequencing (NGS) approaches entered the research setting, there has been a significant decline in sequencing costs. These approaches allow either the whole genome (via whole-genome sequencing [...

The East African region boasts of a number of emerging leaders within Sub-Saharan Africa in terms of overall development and growth. On one hand, the region has one of the highest burdens of disease in the world, such as HIV, malaria, and tuberculosis. On the other hand, there has been a growing trend of non-communicable diseases, such as cancers a...

The African continent grapples with a huge burden of communicable diseases, particularly HIV/AIDS, tuberculosis, and malaria. With African governments facing major health financing challenges, a significant proportion of these disease areas are financed by global aid organizations that are also helping in poverty eradication in the continent. Paral...

he global life science industry is in a state of flux. While the recent years have seen the advent of multiple novel technologies, such as in-vitro diagnostics (IVD), CRISPR-Cas9, virtual clinical trials, and liquid biopsy, the industry stands at a crossroad with challenges in scaling-up and commercializing such technologies. In addition, companies...

Pharmaceutical drug discovery and development suffers from declining success rates with new molecules and the rate of return shrinking from 16Percentage in 2011 to almost 11Percentage in 2018. Frost & Sullivan research indicates that traditional solutions that have focused primarily on data from limited sources and rule-based computational techniqu...